We have located links that may give you full text access.
Journal Article
Review
Emerging trends in the evaluation and management of small cell prostate cancer: a clinical and molecular perspective.
Expert Review of Anticancer Therapy 2016 October
INTRODUCTION: Prostatic small cell carcinoma (PSCC) is a rare, aggressive form of prostate cancer associated with poor clinical outcomes. It can arise de novo or in the setting of castrate resistant adenocarcinoma of the prostate. Current therapeutic interventions are based upon observations the PSCC responds similarly to small cell carcinoma of the lung. Standard treatment includes chemotherapy with cisplatin and etoposide, radiation therapy, and occasional extirpative management. Ongoing research into the molecular pathway behind the development of PSCC and potential interventions is resulting in the identification of multiple novel therapeutic targets.
AREAS COVERED: A review of contemporary literature was undertaken to evaluate the histology, pathogenesis, evolution, current and novel treatment regimens, and upcoming methods of diagnosis of PSCC. To this end a literature search using terms, 'prostate small cell carcinoma', 'neuroendocrine prostate cancer', and derivations thereof was performed with a thorough review of the current literature. Expert commentary: Among current studies, AURKA inhibitors and PAPR1 inhibitors are exciting potential targets with early studies suggesting significant benefit. Continued research into the molecular underpinnings of PSCC is necessary to identify novel targets for early identification of patients with PSCC and to develop optimal treatment regimens.
AREAS COVERED: A review of contemporary literature was undertaken to evaluate the histology, pathogenesis, evolution, current and novel treatment regimens, and upcoming methods of diagnosis of PSCC. To this end a literature search using terms, 'prostate small cell carcinoma', 'neuroendocrine prostate cancer', and derivations thereof was performed with a thorough review of the current literature. Expert commentary: Among current studies, AURKA inhibitors and PAPR1 inhibitors are exciting potential targets with early studies suggesting significant benefit. Continued research into the molecular underpinnings of PSCC is necessary to identify novel targets for early identification of patients with PSCC and to develop optimal treatment regimens.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app